je.st
news
Interim Data from Proof-of-Concept Study of Mercks Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting
2014-11-10 00:53:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Mercks Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
study
presented
Category:Biotechnology and Pharmaceuticals